A Phase II, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Patients With Non-Alcoholic Steatohepatitis
Latest Information Update: 19 Apr 2024
At a glance
- Drugs Fazpilodemab (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms BANFF
- Sponsors Genentech
Most Recent Events
- 14 Nov 2023 Results presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Nov 2023 Status changed to discontinued early for strategic business reasons as per results presented at The Liver Meeting 2023
- 09 Feb 2023 The trial has been completed in France and Belgium, according to Eudra record.